304 related articles for article (PubMed ID: 2892335)
1. Clinical evaluation of SMS 201-995. Long-term treatment in gut neuroendocrine tumours, efficacy of oral administration, and possible use in non-tumoural inappropriate TSH hypersecretion.
Williams G; Anderson JV; Williams SJ; Bloom SR
Acta Endocrinol Suppl (Copenh); 1987; 286():26-36. PubMed ID: 2892335
[TBL] [Abstract][Full Text] [Related]
2. Hyperthyroidism due to non-tumoural inappropriate TSH secretion. Effect of a long-acting somatostatin analogue (SMS 201-995).
Williams G; Kraenzlin M; Sandler L; Burrin J; Law A; Bloom S; Joplin GF
Acta Endocrinol (Copenh); 1986 Sep; 113(1):42-6. PubMed ID: 2876571
[TBL] [Abstract][Full Text] [Related]
3. Long-term treatment of acromegaly with Sandostatin (SMS 201-995). Normalization of most anomalous growth hormone responses.
Pieters GF; van Liessum PA; Smals AG; van Gennep JA; Benraad TJ; Kloppenborg PW
Acta Endocrinol Suppl (Copenh); 1987; 286():9-18. PubMed ID: 2892339
[TBL] [Abstract][Full Text] [Related]
4. Neuroendocrine tumours of the gut: long-term therapy with the somatostatin analogue SMS 201-995.
Anderson JV; Bloom SR
Scand J Gastroenterol Suppl; 1986; 119():115-28. PubMed ID: 2876495
[TBL] [Abstract][Full Text] [Related]
5. Suppression of primary and secondary peptides with somatostatin analog in the therapy of functional endocrine tumors.
Woltering EA; Mozell EJ; O'Dorisio TM; Fletcher WS; Howe B
Surg Gynecol Obstet; 1988 Dec; 167(6):453-62. PubMed ID: 2460958
[TBL] [Abstract][Full Text] [Related]
6. Use of a somatostatin analog (SMS 201-995) in the glucagonoma syndrome.
Altimari AF; Bhoopalam N; O'Dorsio T; Lange CL; Sandberg L; Prinz RA
Surgery; 1986 Dec; 100(6):989-96. PubMed ID: 2878500
[TBL] [Abstract][Full Text] [Related]
7. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
[TBL] [Abstract][Full Text] [Related]
8. Observations on the effect of a somatostatin analog in the Zollinger-Ellison syndrome: implications for the treatment of apudomas.
Ellison EC; O'Dorisio TM; Sparks J; Mekhjian HS; Fromkes JJ; Woltering EA; Carey LC
Surgery; 1986 Aug; 100(2):437-44. PubMed ID: 2426819
[TBL] [Abstract][Full Text] [Related]
9. The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones.
George SR; Hegele RA; Burrow GN
Clin Invest Med; 1987 Jul; 10(4):309-15. PubMed ID: 2888554
[TBL] [Abstract][Full Text] [Related]
10. Different responses to chronic somatostatin analogues in patients with central hyperthyroidism.
Mannavola D; Persani L; Vannucchi G; Zanardelli M; Fugazzola L; Verga U; Facchetti M; Beck-Peccoz P
Clin Endocrinol (Oxf); 2005 Feb; 62(2):176-81. PubMed ID: 15670193
[TBL] [Abstract][Full Text] [Related]
11. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut.
Gorden P; Comi RJ; Maton PN; Go VL
Ann Intern Med; 1989 Jan; 110(1):35-50. PubMed ID: 2535688
[TBL] [Abstract][Full Text] [Related]
12. [Somatostatin analogue in the treatment of neuroendocrine gut tumors].
Ben Yosef R; Glaser B; Catane R
Harefuah; 1990 Jul; 119(1-2):15-8. PubMed ID: 2172125
[TBL] [Abstract][Full Text] [Related]
13. Response of thyrotropin-secreting pituitary adenomas to a long-acting somatostatin analogue.
Comi RJ; Gesundheit N; Murray L; Gorden P; Weintraub BD
N Engl J Med; 1987 Jul; 317(1):12-7. PubMed ID: 2884564
[TBL] [Abstract][Full Text] [Related]
14. Somatostatin analogue (SMS 201-995) in patients with gastrinomas.
Vinik AI; Tsai S; Moattari AR; Cheung P
Surgery; 1988 Nov; 104(5):834-42. PubMed ID: 2903562
[TBL] [Abstract][Full Text] [Related]
15. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995.
Beck-Peccoz P; Mariotti S; Guillausseau PJ; Medri G; Piscitelli G; Bertoli A; Barbarino A; Rondena M; Chanson P; Pinchera A
J Clin Endocrinol Metab; 1989 Jan; 68(1):208-14. PubMed ID: 2491862
[TBL] [Abstract][Full Text] [Related]
16. Long term treatment with the somatostatin analog SMS 201-995 in a patient with a thyrotropin- and growth hormone-secreting pituitary adenoma.
Wémeau JL; Dewailly D; Leroy R; D'Herbomez M; Mazzuca M; Decoulx M; Jaquet P
J Clin Endocrinol Metab; 1988 Mar; 66(3):636-9. PubMed ID: 2895119
[TBL] [Abstract][Full Text] [Related]
17. [Long-term therapy of a metastasizing pancreatic vipoma using the somatostatin derivative octreotide].
Flückiger A; Schlup P
Schweiz Med Wochenschr; 1992 Aug; 122(33):1221-3. PubMed ID: 1326786
[TBL] [Abstract][Full Text] [Related]
18. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases.
Kraenzlin ME; Ch'ng JL; Wood SM; Carr DH; Bloom SR
Gastroenterology; 1985 Jan; 88(1 Pt 1):185-7. PubMed ID: 2856877
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogue (SMS 201-995) in the management of gastroenteropancreatic tumors and diarrhea syndromes.
Vinik AI; Tsai ST; Moattari AR; Cheung P; Eckhauser FE; Cho K
Am J Med; 1986 Dec; 81(6B):23-40. PubMed ID: 2879447
[TBL] [Abstract][Full Text] [Related]
20. Metastatic vipoma arising from colonic primary tumour.
Bradley C; Haddock G; Pickard RG; Rankin EM
Eur J Surg Oncol; 1989 Aug; 15(4):386-9. PubMed ID: 2547666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
